IOB - Delayed Quote EUR

Innate Pharma S.A. (0EVI.IL)

1.7720

+0.0080

+(0.45%)

At close: 2:52:34 PM GMT+1

French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit

Sanofi SA (NASDAQ:SNY) reported Thursday a first-quarter 2025 business operating income of 2.9 billion euros ($3.06 billion), up 20.1% year over year and 18.7% in constant currency. The company reported first-quarter sales of 9.89 billion euros ($10.42 billion), beating the consensus of $9.77 billion. This was driven by launches, Dupixent, and favorable Beyfortus phasing. Sales increased 10.8% year over year and 9.7% on constant currency. U.S. sales were 4.66 billion and increased by 15.4%. The

Benzinga yesterday

SNY

IPH.PA
Innate Pharma Announces €15M Investment by Sanofi

MARSEILLE, France, April 24, 2025--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announces a €14,999,998.59 capital increase subscribed by Sanofi.

Business Wire yesterday

IPHA

IPHYF
Sanofi to Invest $17.2 Million in Innate Pharma as Part of Review of 2016 License Agreement

Innate Pharma SA (IPHA) and Sanofi (SNY) have agreed that the latter will invest up to 15 million eu

PREMIUM
MT Newswires 2 days ago

IPH.PA

SNY
Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi’s Intention to Make a Strategic Investment in the Company

MARSEILLE, France, April 23, 2025--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announce review of their January 2016 Research Collaboration and License Agreement (the "2016 Agreement") with Sanofi:

Business Wire 2 days ago

IPHA

IPHYF
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025

MARSEILLE, France, April 16, 2025--Innate Pharma to hold its Annual General Meeting of shareholders on May 22, 2025

Business Wire 9 days ago

IPHA

IPHYF
Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition

MARSEILLE, France, April 16, 2025--Innate Pharma proposes to its shareholders to transform its corporate governance structure into a board of directors and to change its composition

Business Wire 9 days ago

IPHA

IPHYF
Innate Pharma to Participate in the 2025 Stifel Virtual Targeted Oncology Forum

MARSEILLE, France, April 03, 2025--Innate Pharma to participate in the 2025 Stifel Virtual Targeted Oncology Forum

Business Wire 22 days ago

IPHA

IPHYF
European Penny Stocks To Watch In March 2025

European markets have recently faced challenges, with the pan-European STOXX Europe 600 Index ending about 1.4% lower due to new U.S. trade tariffs, despite earlier optimism from positive economic updates and geopolitical developments. In such a climate of uncertainty, investors often turn their attention to penny stocks—smaller or less-established companies that can offer unique value propositions. While the term "penny stocks" may seem outdated, these investments can still provide...

Simply Wall St. 25 days ago

IPHA

IPHYF

AGF-B.CO
Innate Pharma SA (IPHA) (FY 2024) Earnings Call Highlights: Strategic Advances and Financial ...

Innate Pharma SA (IPHA) showcases robust R&D progress and financial resilience, despite increased operational expenses and competitive challenges.

GuruFocus.com 28 days ago

IPH.PA

SNY
Innate Pharma Reports Full Year 2024 Financial Results and Business Update

MARSEILLE, France, March 27, 2025--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today reported its consolidated financial results for the year ending December 31, 2024. The consolidated financial statements are attached to this press release.

Business Wire 29 days ago

IPHA

IPHYF
Innate Pharma Highlights Antibody Drug Conjugate IPH4502 Abstract Selected for the AACR 2025 Annual Meeting

MARSEILLE, France, March 26, 2025--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that an abstract regarding IPH4502, its novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) targeting Nectin-4, has been selected for the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30 in Chicago, Illinois.

Business Wire 30 days ago

IPHA

IPHYF
Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference

MARSEILLE, France, March 25, 2025--Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference

Business Wire last month

IPHA

IPHYF
Innate Pharma Announces Conference Call and Webcast for Full Year 2024 Financial Results

MARSEILLE, France, March 20, 2025--Innate Pharma announces conference call and webcast for full year 2024 financial results

Business Wire last month

IPHA

IPHYF
Innate Pharma to Participate in the 2025 Leerink Partners Global Healthcare Conference

MARSEILLE, France, February 27, 2025--Innate Pharma to participate in The 2025 Leerink Partners Global Healthcare Conference

Business Wire last month

IPHA

IPHYF
Innate’s lacutamab gains FDA breakthrough therapy designation

The FDA’s designation for the antibody follows positive results from Phase I and II trials.

Pharmaceutical Technology 2 months ago

IPH.PA
$Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome$

Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome

MARSEILLE, France, February 17, 2025--Innate Pharma announces U.S. FDA granted Breakthrough Therapy Designation to lacutamab for relapsed or refractory Sézary Syndrome

Business Wire 2 months ago

IPHA

IPHYF
3 Promising Penny Stocks With Market Caps Under US$500M

As global markets continue to march toward record highs, driven by optimism around tariffs and AI developments, investors are increasingly looking for opportunities in smaller-cap stocks. Penny stocks, while often associated with higher risk, can still offer significant potential when backed by strong financials and clear growth prospects. This article will explore three such penny stocks that stand out due to their balance sheet strength and promising potential for future gains.

Simply Wall St. 2 months ago

YSASF

0314.HK

IPHA
Innate Pharma doses first patient in Nectin-4 ADC trial

The Phase I trial will evaluate the safety and efficacy of the company’s drug which targets tumours whilst leaving normal cells unharmed.

Clinical Trials Arena 2 months ago

IPH.PA
Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors

MARSEILLE, France, January 27, 2025--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced the first patient was dosed in its Phase 1 study (NCT06781983), investigating the safety and tolerability of IPH4502, an innovative Antibody-Drug Conjugate (ADC), in patients with advanced solid tumors known to express Nectin-4.

Business Wire 2 months ago

IPHA

IPHYF
Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York

MARSEILLE, France, January 21, 2025--Innate Pharma announces Nectin-4 antibody drug conjugate investor and analyst event in New York

Business Wire 3 months ago

IPHA

IPHYF

Performance Overview

Return	0EVI.IL	CAC 40 (^FCHI)
YTD	-8.75%	+2.11%
1-Year	-19.64%	-5.99%
3-Year	-34.85%	+16.85%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Innate Pharma S.A. (0EVI.IL)

French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit

Innate Pharma Announces €15M Investment by Sanofi

Sanofi to Invest $17.2 Million in Innate Pharma as Part of Review of 2016 License Agreement

Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi’s Intention to Make a Strategic Investment in the Company

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025

Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition

Innate Pharma to Participate in the 2025 Stifel Virtual Targeted Oncology Forum

European Penny Stocks To Watch In March 2025

Innate Pharma SA (IPHA) (FY 2024) Earnings Call Highlights: Strategic Advances and Financial ...

Innate Pharma Reports Full Year 2024 Financial Results and Business Update

Innate Pharma Highlights Antibody Drug Conjugate IPH4502 Abstract Selected for the AACR 2025 Annual Meeting

Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference

Innate Pharma Announces Conference Call and Webcast for Full Year 2024 Financial Results

Innate Pharma to Participate in the 2025 Leerink Partners Global Healthcare Conference

Innate’s lacutamab gains FDA breakthrough therapy designation

Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome

3 Promising Penny Stocks With Market Caps Under US$500M

Innate Pharma doses first patient in Nectin-4 ADC trial

Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors

Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York

Performance Overview